Immunic AG | WebDisclosure

PRESS RELEASE

published on 10/29/2024 at 11:30, 1 year 9 months ago

Immunic to Participate in Industry, Scientific and Investor Conferences in November
Immunic to participate in industry, scientific, and investor conferences in November 2024, presenting data on IMU-856 for celiac disease. Details on events and presentations available on company website

Clinical Trials Conférences Investor Immunic Scientific
BRIEF

published on 10/22/2024 at 12:35, 1 year 9 months ago

Immunic Reports Positive Interim Results for Phase 3 ENSURE Program

Biotechnology Vidofludimus Calcium Phase 3 Trials Relapsing Multiple Sclerosis Interim Analysis
BRIEF

published on 10/22/2024 at 12:35, 1 year 9 months ago

Immunic annonce des résultats intermédiaires positifs pour la phase 3 du programme ENSURE

Biotechnologie Essais De Phase 3 Vidofludimus Calcique Sclérose En Plaques Récurrente Analyse Intermédiaire
PRESS RELEASE

published on 10/22/2024 at 12:30, 1 year 9 months ago

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
Immunic announces positive outcome of interim analysis of Phase 3 ENSURE Program for vidofludimus calcium in RMS. Trials recommended to continue unchanged till 2026

Multiple Sclerosis Immunic Vidofludimus Calcium Phase 3 ENSURE Program
BRIEF

published on 09/18/2024 at 12:35, 1 year 11 months ago

Immunic Unveils Promising Vidofludimus Calcium Data at ECTRIMS Congress

Multiple Sclerosis Immunic Vidofludimus Calcium Neuroprotection ECTRIMS 2024
BRIEF

published on 09/18/2024 at 12:35, 1 year 11 months ago

Immunic dévoile des données prometteuses sur le vidofludimus calcique au congrès ECTRIMS

Sclérose En Plaques Neuroprotection Immunique Vidofludimus Calcique ECTRIMS 2024
PRESS RELEASE

published on 09/18/2024 at 12:30, 1 year 11 months ago

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
Immunic presents key Vidofludimus Calcium data at the 40th Congress of ECTRIMS, highlighting its therapeutic potential in Multiple Sclerosis. Immunic, Inc. (Nasdaq: IMUX) showcases findings at the conference in Copenhagen, Denmark

Multiple Sclerosis Immunic Vidofludimus Calcium Therapeutic Potential ECTRIMS
BRIEF

published on 09/04/2024 at 12:35, 1 year 11 months ago

Immunic Enrolls First Patient in Phase 2 Trial for Post COVID Syndrome

Clinical Trial Vidofludimus Calcium Post COVID Syndrome Fatigue Treatment Epstein-Barr Virus
BRIEF

published on 09/04/2024 at 12:35, 1 year 11 months ago

Immunic recrute son premier patient pour un essai de phase 2 sur le syndrome post-COVID

Essai Clinique Vidofludimus Calcique Syndrome Post-COVID Traitement De La Fatigue Virus D'Epstein-Barr
PRESS RELEASE

published on 09/04/2024 at 12:30, 1 year 11 months ago

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
Immunic announces enrollment of the first patient in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium for Post COVID Syndrome. Study aims to suppress EBV reactivation and fatigue symptoms

Clinical Trial Immunic Vidofludimus Calcium Phase 2 Post COVID Syndrome

Published on 08/21/2026 at 13:30, 1 hour 52 minutes ago

BULGOLD Announces Filing Of Financial Results For the Six Months Ended June 30, 2026
Published on 08/21/2026 at 02:30, 12 hours 52 minutes ago

PPX Mining Announces Completion of Debt Settlement
Published on 08/21/2026 at 00:00, 15 hours 22 minutes ago

Apex Confirms Favourable Monazite and Bastnaesite Mineralogy at the Rift Rare Earth Project
Published on 08/20/2026 at 23:00, 16 hours 22 minutes ago

EQ Inc. Reports Second Quarter 2026 Financial Results
Published on 08/20/2026 at 22:00, 17 hours 22 minutes ago

Gold Terra Closes Third and Final Tranche of Its LIFE Offering for Gross Proceeds of Approximately C$10.1 M

View all ACCESSWIRE

Published on 08/21/2026 at 15:18, 3 minutes ago

Form 8.3 - The Vanguard Group, Inc.: SEGRO plc
Published on 08/21/2026 at 15:17, 4 minutes ago

Form 8.3 - The Vanguard Group, Inc.: DCC plc
Published on 08/21/2026 at 15:15, 7 minutes ago

O3 Holding GmbH - Publication Q2 2026 Interim Report
Published on 08/21/2026 at 15:12, 10 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Beazley plc
Published on 08/21/2026 at 15:11, 10 minutes ago

Form 8.3 - The Vanguard Group, Inc.: LondonMetric Property plc

View all EQS

Published on 08/21/2026 at 08:30, 6 hours 52 minutes ago

Thales issues a €1bn bond
Published on 08/21/2026 at 08:30, 6 hours 52 minutes ago

Thales émet un emprunt obligataire de 1 Md€
Published on 08/18/2026 at 18:00, 2 days 21 hours ago

KLARSEN : Nomonation Olivier Cornelis DG ITL et webinaire
Published on 08/18/2026 at 17:45, 2 days 21 hours ago

Mise à disposition du rapport financier annuel 2025-26
Published on 08/18/2026 at 11:15, 3 days 4 hours ago

GUILLEMOT CORPORATION | Déclaration hebdomadaire des transactions sur actions propres du 10 au 14 août 2026

View all LES ECHOS COMFI WIRE

News